GlassScriptPhysician profile
Ross Pinson
NPI 1902242035
$4,726.58
in general payments reported to CMS, 2019-2025
30 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,636 · 2020: $134 · 2021: $171 · 2022: $238 · 2023: $301 · 2024: $691 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $1,412.69 | 2019 | |
| Abbvie INC. | $778.36 | 2020-2025 | |
| Boston Scientific Corporation | $478.21 | 2019-2025 | Overstitch Endoscopic Suturing System |
| Celgene Corporation | $264.63 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $216.62 | 2024-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $198.15 | 2020-2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $197.24 | 2024-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $164.76 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $141.81 | 2025 | Rezdiffra |
| Lilly USA, LLC | $134.59 | 2024-2025 | Omvoh |
| Steris Corporation | $117.46 | 2022 | |
| Genzyme Corporation | $98.38 | 2024-2025 | |
| Qol Medical, LLC | $91.02 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $88.17 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $44.21 | 2025 | Suflave, Sutab |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.29 | 2024-2025 | Xifaxan |
| Enterra Medical, INC. | $35.19 | 2025 | |
| Pfizer INC. | $30.61 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.80 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.61 | 2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $18.04 | 2024 | |
| Medtronic, INC. | $17.51 | 2023 | Manoscan |
| Ironwood Pharmaceuticals, INC | $16.75 | 2024 | |
| Eagle Pharmaceuticals, INC. | $15.77 | 2023 | |
| Celltrion USA INC. | $15.60 | 2025 | Vegzelma |
| Astrazeneca Pharmaceuticals LP | $15.07 | 2023 | |
| Amag Pharmaceuticals, INC. | $14.68 | 2019 | |
| Evoke Pharma, INC. | $13.74 | 2025 | |
| Aimmune Therapeutics, INC. | $13.53 | 2025 | Zenpep |
| Advanced Oxygen Therapy INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Pinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.